Abstract
Objective To assess impacts of government changes to prescription medicine co-payments on individuals’ out-of-pocket prescription medicine expenditure.
Methods Data from The Irish Longitudinal Study on Ageing were used. Participants were community-dwelling adults aged ≥56 years. Ireland has two prescription cost-sharing schemes: the General Medical Services (GMS) scheme (primarily for low-income populations), involving a low monthly payment cap and low co-payments, and the Drugs Payment Scheme (DPS) (for others), with a higher cap and no co-payment limit. We modelled changes to these schemes implemented between 2016-2022 using 2016 data, assessing impacts on out-of-pocket prescription medicine expenditure across participant characteristics.
Results Among 4,155 participants with out-of-pocket prescription medicine expenditure, estimated mean annual prescription medicine expenditure for GMS-eligible participants reduced from €117 (95%CI=€114-120) to €55 (95%CI=€54-€56) due to post-2016 scheme changes. For DPS-eligible participants it reduced from €719 (95%CI=€694-€744) to €555 (95%CI=€541-€569). Those on more medicines had greater savings, with similar savings across income groups.
Conclusions Co-payment changes led to average savings of €62 for GMS-eligible participants and €174 for DPS-eligible participants. Although absolute savings were smaller for GMS participants, these were likely more impactful for this low-income population. Further reductions in monthly caps and co-payment charges, particularly for low-income populations, warrant consideration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the Health Research Board in Ireland (HRB) through an Investigator Led Projects grant (grant number ILP-HSR-2019-006). JL, CP, and LTM were supported by this grant. TILDA is funded by the Irish Government (the Department of Health), the HRB, Atlantic Philanthropies, and Irish Life plc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the TILDA study was received from the Trinity College Research Ethics Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.